Watershed cerebral infarction
Conditions
Interventions
Group A:Agatreban and dual antiplatelet group
Group B:Dual antiplatelet group
Group C:argatroban group
Sponsors
Affiliated Hospital of Jiujiang University
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with acute ischemic stroke within 0-48 hours of onset; 2. Not suitable for or refuse thrombolysis or endovascular treatment; 3. Aged 40 to 75 years; 4. Baseline NIHSS score 1-8 points; 5. After admission, MRI/DWI/CTA was diagnosed as watershed cerebral infarction (responsible for large artery stenosis with or without occlusion), and magnetic sensitivity (SWI or T2*) showed = 1.5 T; 7. The patient and the legal representative are able and willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. There are serious neurological deficits (mRS>=2) before the onset; 2. Within 3 months before admission, have a craniocerebral injury or undergo intracranial or intraspinal surgery, or have a history of intracranial hemorrhage and stroke, intracranial tumor, moyamoya disease, arteriovenous malformation or aneurysm; 3. Received major surgery or severe trauma within 1 month before admission, or had gastrointestinal or urethral bleeding; had an incompressible arterial puncture within 1 week before admission; 4. Active bleeding disease, with obvious bleeding tendency (obvious coagulation dysfunction); abnormal coagulation function (PLT 1.7, aPTT > 40s, or PT > 15s), coagulation factor Lack of patients 5. After blood pressure control, the systolic blood pressure is still >= 220mmHg or the diastolic blood pressure is still >= 120mmHg; 6. Cardiogenic embolism, valvular heart disease, atrial fibrillation, sick sinus, second to third degree atrioventricular block; 7. Those who need to take anticoagulant drugs other than argatroban at the same time, or those who have used anticoagulant drugs in the past week; 8. Those who are allergic to argatroban; 9. Pregnancy or lactation; 10. Those who are contraindicated in the use of aspirin or clopidogrel; (1) Aspirin is forbidden: allergic to aspirin or other salicylates, or any other ingredients of medicines; history of asthma caused by salicylate or salicylic acid substances, non-steroidal anti-inflammatory drugs; acute gastrointestinal ulcers; Bleeding constitution; severe renal failure; severe liver failure; severe heart failure; combined with methotrexate, the last trimester of pregnancy; (2) Clopidogrel is forbidden: allergic to clopidogrel or any component of the preparation, severe liver damage, active pathological bleeding, or digestive tract ulcer or intracranial hemorrhage) 11. Watershed infarction caused by other special reasons: bilateral watershed cerebral infarction caused by systemic hypotension or global cerebral hypoperfusion, severe anemia, eosinophilia, parasitic infection, toxicity caused by cyclosporine treatment, primary Central nervous system vasculitis, autosomal dominant cerebral arterial disease (CADASIL) with subcortical infarction and leukoencephalopathy, and watershed cerebral infarction caused by malignant-associated coagulopathy; 12. MRI confirmed patients with multiple intracranial microhemorrhage (CMBs>=10) or cerebrovascular amyloidosis; 13. Severe systemic diseases, such as severe heart, lung, liver, and kidney failure; 14. Participating in other studies that have an impact on this research; 15. The investigator assesses other situations that are not suitable for participating in this drug study (such as dementia, combined mental or mental illness, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of progressive cerebral infarction within 1 week after randomization; | — |
Countries
China
Contacts
Public ContactYin Xiaoping
Affiliated Hospital of Jiujiang University
Outcome results
None listed